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Some 50 to 60 years ago, Prof. Takeru Higuchi
and his coworkers laid the foundation of
modern tableting technology by publishing a
series of papers on the ‘Physics of Tablet
Compression’ (1, 2). Since then there has been
additional progress in tableting technology,
especially to meet material and processing
needs of high-speed tablet presses. However,
tableting of drug substances still remains an
expensive, time-consuming and labor intensive
batch process consisting of multiple unit
operations. Large amounts of excipients are
required to overcome deficiencies of drug
substances with respect to their compactibility,
flow, bulk density and other attributes
necessary for tableting, which make the tablet
size large, particularly creating challenges with
the formulation of large-dose tablets and bilayer
tablets. Because of the use of multiple unit
operations, any progress towards continuous
manufacture of tablets to gain production
efficiency has also been limited.  It is expected
that the situation may change in the near future
due to the recent introduction of an advanced
melt granulation technology in the
pharmaceutical field, where drug substances are
granulated with thermoplastic polymers at
elevated temperatures using twin-screw
extruders to improve their compactibility and
processability.
Most drug substances are inherently non-
compactible, i.e, their powders may not be
compressed into tablets with acceptable
hardness. Three common methods are generally
used to process drug substances into tablets,
i.e., (i) direct compression by blending active
ingredients with relatively large amounts of
excipients, (ii) wet granulation of drug-excipient
mixtures using low- or high-shear granulators
and sometimes fluid-bed granulators, and (iii)
roller compaction of drug-excipient mixtures
(3). Direct compression is a simple two-step
process of mixing and compression. The
introduction of microcrystalline cellulose in the
1960s (4) and of coprocessed excipients later
(5) made direct compression of drug substances
into tablets possible. However, the drug
content in a tablet formulation intended for
direct compression may not exceed 30-40 %,
and even then many drug substances may not
be directly compressed because of inadequate
compactibility, poor powder flow, segregation
of powders and lack of content uniformity. The
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powder flow and compactibility become special
issues for poorly water soluble drugs that
usually require milling into very fine powders.
For these reasons, only a small fraction of
currently marketed tablets are manufactured by
direct compression. Both wet granulation and
roller compaction are more versatile methods
than direct compression. They are, however,
more complex processes requiring multiple unit
operations (3). These processes also require
large amounts of excipients, the typical drug
content being 50% or less.
In addition to wet granulation and roller
compaction, melt granulation has also been
investigated in the pharmaceutical field for a
long time. However, it has rarely been used for
large scale manufacture of tablets. In the
conventional melt granulation process, drug
substances are granulated with waxes, lipids,
polyethylene glycols, etc., in heated high-shear
granulators. The melting temperatures of the
granulating agents used are usually > 50°C, but
seldom exceed 90°C (6). Due to the presence of
such low-melting waxy materials, the granules
produced may not have desirable attributes for
tableting.
In the past 3 to 4 years, there have been several
reports in the literature where twin-screw
extruders have been used to convert drug
substances into granules or particulates
providing good flow and high compactibility (7-
9). The tablets produced also exhibit low
friability. Lakshman et al. (7) mixed 90% w/w
m e t f o r m i n  H C l  w i t h  1 0 %  w / w
hydroxypropylcellulose (HPC) and passed them
through a twin-screw extruder at different
temperatures ranging from 140 to 180°C, which
were below the melting temperature of the drug
substance (224 °C) but above the glass
transition temperature (Tg) of HPC (130 °C).
No dies were used at the end of extruder
barrels to facilitate extrusion of the granules. At
the granulation temperature, the drug substance
remained as dry powder while the polymer
converted into the rubbery state. Granules were
formed because of the high shear energy
imparted by the extruder to such a drug-
polymer mixture. The polymer transitioned
back into the amorphous state when the
granules extruded from the heated barrels and
cooled to the ambient room temperature. The
granules were milled if, necessary, to convert
them into a uniform particle size. It was
postulated that the amorphous polymers
formed bridges in between the drug particles in
the granules and they also coated the surface of
the granules, both of which created much
stronger inter-particulate bonding during
tableting.
Granules with excellent tabletability could be
obtained with 10% w/w or less polymer. The
densification of materials within the extruder
barrels occurs due to pressure generated by the
screw elements as well as by the restriction of
flow created by the positive conveying of
materials into the kneading elements.
Therefore, the design and arrangement of screw
elements, screw speed, feed rate, barrel
temperature and torque generated within the
barrel are some of the critical process variables
when using twin-screw extruders for melt
granulation. Depending on the needs of the
drug formulation, polymers with different Tg,
melt viscosity and hydrophilicity may be used
during the twin-screw melt granulation. The
physicochemical properties of several such
polymers are reported in a series of three
papers published in the present issue of this
Journal.
In a separate study using the twin screw melt
granulation process, Vasanthavada et al. (8) used
mixtures of HPC and ethylcellulose (EC) at a
drug substance to polymer ratio of 90:10 w/w
to formulate extended release tablets of
imatinib mesylate. Research thus shows that the
technology can be used for both immediate and
modified release tablets. Greater amounts of
polymers, as well as, other excipients may be
used, if necessary, to meet specific formulation
needs, such as dissolution rate, bioavailability
enhancement, etc.
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Since relatively small amounts of excipients can
be used to produce acceptable tablets, the
process is especially suitable for high-dose
tablets in order to keep the tablet size smaller.
It is also suitable for bi-layer tablets, where it is
often necessary to reduce the size of a layer to
maintain the overall tablet weight relatively
small. Even for a relatively low-dose tablet, the
twin-screw melt granulation process would lead
to cost savings as lower amounts of excipients
would be needed and, due to the lower tablet
weight, a particular batch size would produce
more tablets. It is expected that the twin-screw
melt granulation process could also result in a
new generation of co-processed excipients,
where currently available pharmaceutical
excipients could be converted to better
compactible and flowable forms by co-
granulating them with suitable polymers. One
concern for the process is the possible
degradation of drug substances during melt
granulation at high temperature. Most drug
substances may, however, not be susceptible to
degradation since they are granulated below
their melting temperatures and additionally tend
to be exposed to these temperatures only for a
very short time. Even when such a possibility
exists, suitable polymeric excipients may be
available that can be extruded at a relatively
lower temperature.
The manufacturing processes in the
pharmaceutical industry have not kept pace
with time (10). Pharmaceutical equipment and
process capability are outdated when compared
with the benchmarks of what can be achieved
and what should be achievable. Although not
directly comparable, pharmaceutical processes
operate far below the performance and
efficiency levels attained by the semiconductor
and other consumer products manufacturing
practices. This situation results in high
manufacturing costs and possible delays in
bringing the product to the market. Product
failure due to suboptimal manufacturing
processes may be detrimental to a
pharmaceutical company. Since tableting is still,
by scale, the most common manufacturing
process in the pharmaceutical industry (an
estimated more than 3 out of 4 dosage units
taken by patients are tablets), an improvement
in tableting technology could greatly benefit the
industry and ultimately patients. As opposed to
other granulation techniques mentioned above, 
melt granulation using twin-screw extruders can
be automated for continuous manufacturing of
tablets (11). The pharmaceutical Quality-by-
Design paradigms can be adapted to the melt
granulation process and each step of the
process can be monitored using inline process
analytical technology (PAT). There are multiple
reports that melt granulation using twin-screw
extruders has already been scaled up to the
large commercial scale manufacture of tablets
and the finished drug products are on the
market.
In a recent editorial of this Journal (12),
Moreton asked: “How can the chances of
developing robust products be boosted?”
According to him, “the answer lies in improved
knowledge and understanding of excipients,
APIs and unit operations involved in the
manufacture of the medicinal product, and how
they interact to produce robust formulations
and products.” The answer cannot be truer in
case of the tableting technology, where it is
expected that the availability of a wide array of
polymeric excipients, the recent introduction of
melt granulation technologies using twin screw
extruders, and the interrelationship between
excipients and technology will bring major
changes in how tablets are formulated and
produced in the future. More research is needed
to ensure that such innovations are widely
applied in the pharmaceutical field.
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